2024年9月，美国圣地亚哥，全球顶级肺癌学术会议现场。一组数据被投放在大屏幕上：接受依沃西治疗的患者，中位无进展生存期11.1个月；对照组——默沙东的“K药”帕博利珠单抗——5.8个月。台下静了一瞬，然后是窃窃私语，接着是此起彼伏的祝贺。这是全球首个在头对头III期临床试验中击败“药王”K药的药物。而做出这款药的，是一家中国公司，一个女人带领的中国公司。消息传回国内，次日康方生物股价大涨16%。...
Source Link2024年9月，美国圣地亚哥，全球顶级肺癌学术会议现场。一组数据被投放在大屏幕上：接受依沃西治疗的患者，中位无进展生存期11.1个月；对照组——默沙东的“K药”帕博利珠单抗——5.8个月。台下静了一瞬，然后是窃窃私语，接着是此起彼伏的祝贺。这是全球首个在头对头III期临床试验中击败“药王”K药的药物。而做出这款药的，是一家中国公司，一个女人带领的中国公司。消息传回国内，次日康方生物股价大涨16%。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.